

University of Dundee

## Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk

Sheth, Harsh; Northwood, Emma; Ulrich, Cornelia M.; Scherer, Dominique; Elliott, Faye; Barrett, Jennifer H.

*Published in:*  
PLoS ONE

*DOI:*  
[10.1371/journal.pone.0192223](https://doi.org/10.1371/journal.pone.0192223)

*Publication date:*  
2018

*Licence:*  
CC BY

*Document Version*  
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

### *Citation for published version (APA):*

Sheth, H., Northwood, E., Ulrich, C. M., Scherer, D., Elliott, F., Barrett, J. H., Forman, D., Wolf, C. R., Smith, G., Jackson, M. S., Santibanez-Koref, M., Haile, R., Casey, G., Jenkins, M., Win, A. K., Hopper, J. L., Marchand, L. L., Lindor, N. M., Thibodeau, S. N., ... Bishop, D. T. (2018). Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations. *PLoS ONE*, 13(2), 1-17. [e0192223]. <https://doi.org/10.1371/journal.pone.0192223>

### **General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

RESEARCH ARTICLE

# Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations

Harsh Sheth<sup>1,2☯\*</sup>, Emma Northwood<sup>2☯</sup>, Cornelia M. Ulrich<sup>3</sup>, Dominique Scherer<sup>4</sup>, Faye Elliott<sup>2</sup>, Jennifer H. Barrett<sup>2</sup>, David Forman<sup>2</sup>, C. Roland Wolf<sup>5</sup>, Gillian Smith<sup>5</sup>, Michael S. Jackson<sup>1</sup>, Mauro Santibanez-Koref<sup>1</sup>, Robert Haile<sup>6</sup>, Graham Casey<sup>7</sup>, Mark Jenkins<sup>8</sup>, Aung Ko Win<sup>8</sup>, John L. Hopper<sup>8</sup>, Loic Le Marchand<sup>9</sup>, Noralane M. Lindor<sup>10</sup>, Stephen N. Thibodeau<sup>11</sup>, John D. Potter<sup>12</sup>, John Burn<sup>1</sup>, D. Timothy Bishop<sup>2\*</sup>


**1** Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, **2** Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom, **3** Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States of America, **4** Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany, **5** School of Medicine, University of Dundee, Dundee, United Kingdom, **6** Stanford Cancer Institute, Stanford, California, United States of America, **7** Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia, United States of America, **8** Melbourne School of Population and Global Health, The University of Melbourne, Carlton, Australia, **9** University of Hawaii, Manoa, Hawaii, United States of America, **10** Mayo Clinic, Scottsdale, Arizona, United States of America, **11** Mayo Clinic, Rochester, Minnesota, United States of America, **12** Centre for Public Health Research, Massey University, Wellington, New Zealand

☯ These authors contributed equally to this work.

\* [harsh.sheth2@newcastle.ac.uk](mailto:harsh.sheth2@newcastle.ac.uk) (HS); [D.T.Bishop@leeds.ac.uk](mailto:D.T.Bishop@leeds.ac.uk) (DTB)

## Abstract

Regular aspirin use is associated with reduced risk of colorectal cancer (CRC). Variation in aspirin's chemoprevention efficacy has been attributed to the presence of single nucleotide polymorphisms (SNPs). We conducted a meta-analysis using two large population-based case-control datasets, the UK-Leeds Colorectal Cancer Study Group and the NIH-Colon Cancer Family Registry, having a combined total of 3325 cases and 2262 controls. The aim was to assess 42 candidate SNPs in 15 genes whose association with colorectal cancer risk was putatively modified by aspirin use, in the literature. Log odds ratios (ORs) and standard errors were estimated for each dataset separately using logistic regression adjusting for age, sex and study site, and dataset-specific results were combined using random effects meta-analysis. Meta-analysis showed association between SNPs rs6983267, rs11694911 and rs2302615 with CRC risk reduction (All  $P < 0.05$ ). Association for SNP rs6983267 in the *CCAT2* gene only was noteworthy after multiple test correction ( $P = 0.001$ ). Site-specific analysis showed association between SNPs rs1799853 and rs2302615 with reduced colon cancer risk only ( $P = 0.01$  and  $P = 0.004$ , respectively), however neither reached significance threshold following multiple test correction. Meta-analysis of SNPs rs2070959 and rs1105879 in *UGT1A6* gene showed interaction between aspirin use and CRC risk ( $P_{\text{interaction}} = 0.01$  and  $0.02$ , respectively); stratification by aspirin use showed an association for decreased CRC risk for aspirin users having a wild-type genotype (rs2070959



## OPEN ACCESS

**Citation:** Sheth H, Northwood E, Ulrich CM, Scherer D, Elliott F, Barrett JH, et al. (2018) Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations. PLoS ONE 13(2): e0192223. <https://doi.org/10.1371/journal.pone.0192223>

**Editor:** Zongli Xu, National Institute of Environmental Health Sciences, UNITED STATES

**Received:** May 17, 2017

**Accepted:** January 19, 2018

**Published:** February 9, 2018

**Copyright:** © 2018 Sheth et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** Anonymized UK-CCSG data are available in the Supporting Information files. The original UK-CCSG data are available at request from D. Timothy Bishop (email: [D.T.Bishop@leeds.ac.uk](mailto:D.T.Bishop@leeds.ac.uk)). The NIH-CCFR data are available at request from Allyson Templeton (email: [atemplet@fredhutch.org](mailto:atemplet@fredhutch.org)). Others would be able to access these data in the same manner as the authors and the authors did not have any special access privileges that others would not have.

**Funding:** The UK-CCSG study was supported by the Cancer Research UK grant C588/A19167. The NIH-CCFR study was supported by grant UM1 CA167551 from the National Cancer Institute and through cooperative agreements with the following CCFR centers: Australasian Colorectal Cancer Family Registry (U01 CA074778 and U01/U24 CA097735), Ontario Familial Colorectal Cancer Registry (U01/U24 CA074783) and Seattle Colorectal Cancer Family Registry (U01/U24 CA074794). The Colon CFR Illumina GWAS was supported by funding from the National Cancer Institute, National Institutes of Health (U01 CA122839 and R01 CA143237 to Graham Casey). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the Colon Cancer Family Registry (CCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the CCFR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** John Burn and Cornelia M. Ulrich are consultant/advisory board member of Bayer Pharma who manufacture aspirin. Other authors have declared that no competing interest exist. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

OR = 0.77, 95% CI = 0.68–0.86; rs1105879 OR = 0.77 95% CI = 0.69–0.86) compared to variant allele carriers. The direction of the interaction however is in contrast to that published in studies on colorectal adenomas. Both SNPs showed potential site-specific interaction with aspirin use and colon cancer risk only ( $P_{\text{interaction}} = 0.006$  and  $0.008$ , respectively), with the direction of association similar to that observed for CRC. Additionally, they showed interaction between any non-steroidal anti-inflammatory drugs (including aspirin) use and CRC risk ( $P_{\text{interaction}} = 0.01$  for both). All gene x environment (GxE) interactions however were not significant after multiple test correction. Candidate gene investigation indicated no evidence of GxE interaction between genetic variants in genes involved in aspirin pathways, regular aspirin use and colorectal cancer risk.

## Introduction

Observational studies have consistently demonstrated an association between regular aspirin or other non-steroidal anti-inflammatory drug (NSAID) use and reduced colorectal cancer (CRC) risk [1]. For CRC, a randomized chemopreventive trial in patients with Lynch syndrome showed beneficial effect of aspirin use in reducing CRC risk, and in the general population, long-term risk reduction is most evident from follow-up of the cardiovascular disease prevention trials conducted in the 1980s [1–4]. Optimizing chemoprevention requires understanding the factors that limit the full impact of aspirin dosage. Advances in elucidating aspirin's mode of action on cellular pathways within the colonic epithelium have been made; in particular- inhibition of cyclooxygenase activity, inhibition of NF- $\kappa$ B, induction of polyamine catabolism and downregulation of WNT- $\beta$ -catenin signalling [5–9]. Although, further work is required to fully clarify these mechanisms. Delineating interaction of aspirin and its metabolites with molecules involved in key cellular processes associated with tumorigenesis could not only help validate variation in the chemopreventive efficacy but also aid in understanding the neoplastic transformation of colonic epithelial cells [10]. Furthermore, identifying gene x environment (GxE) interactions between genetic markers and aspirin use could help in stratifying individuals who would most benefit (or not benefit) from taking aspirin.

Inter-individual variation in the chemopreventive effect on colorectal neoplasia has been in part attributed to germline variations, particularly single nucleotide polymorphisms (SNPs). Whilst a large number of SNPs in aspirin's pharmacokinetic and pharmacodynamic pathways have been suggested to modulate chemopreventive effect in observational studies [6, 9, 11–17], these associations have not been replicated. Furthermore, a large genome-wide association study (GWAS) carried out Nan *et al* 2015, investigated potential GxE interactions based on regular use of any NSAIDs (including aspirin) as exposure [6]. Whilst, such GWAS studies offer a “hypothesis-free” approach to test for association between variants and phenotype of interest, the statistical cost of extreme multiple testing compromises power; candidate gene approach utilises an *a priori* biologically-motivated hypothesis to assess association between variants in putative genes and phenotype of interest. Hence, the techniques are complementary approaches to identifying potential sources of GxE interactions within observational studies.

To our knowledge, no meta-analysis has been reported in the literature which tested for GxE interaction between SNPs in aspirin pathway genes, regular aspirin use and CRC risk. Therefore, the current study aimed to assess associations of candidate SNPs that putatively modify aspirin's pharmacological effects by carrying out random effects meta-analysis of GxE interaction between aspirin only use and CRC risk using two large population based case-

control datasets: UK-Colorectal Cancer Study Group (UK-CCSG) and NIH- Colon Cancer Family Registry (NIH-CCFR).

## Materials and methods

### Study samples and epidemiological questionnaire

Individual level data from the UK-CCSG (recruitment 1997–2013) and NIH-CCFR Phase I (recruitment in Australia, Canada and the USA, 1997–2002) case-control datasets were pooled. Both studies enrolled incident CRC cases and healthy population controls [18, 19].

From the UK-CCSG dataset, CRC cases and controls from all three study sites (Leeds, Dundee and York) were included in the analysis. Briefly, cases between the age of 45 and 80 years with histologically confirmed incident CRC and diagnosed in the period of 1997–2000, were identified at all three sites while for 2000–2013 only from Leeds. Patients who had a primary cancer previously, history of coeliac disease, familial adenomatous polyposis, diverticular disease 2 years before current cancer diagnosis, non-adenocarcinoma colorectal cancer or ulcerative colitis diagnosed in previous 3 years were not recruited in the study. Healthy population based controls were identified through patient's GP practice list. An age and sex matched control with no history of previous cancer at the time of recruitment was identified for each case between 1997 and 2000 at all 3 sites, and following 2000, friends or spouse of cases from Leeds site with no history of cancer at the time of recruitment were collected for the study to complement GP recruitment.

From the NIH-CCFR dataset, CRC cases and controls from three study sites (Ontario, Melbourne and Fred Hutchinson Cancer Research Centre) were included in the analysis. Despite availability of epidemiological data on cases and controls from the three other NIH-CCFR sites (University of Southern California, Mayo Clinic and Hawaii), these sites were excluded from the analysis due to the absence of genome-wide SNP genotype data for controls. For the current study, incident case proband identified through population based cancer registries recruited between 1997 and 2002 were included in the analysis. Healthy population based and spouse controls were identified through medicare and driver's license files, telephone subscriber lists and electoral rolls and were randomly selected between 1997 and 2002.

For the UK-CCSG dataset, a research nurse carried out interviews of the study participants either in hospital or at home. All participants completed detailed diet and lifestyle questionnaire called the Food Frequency and Epidemiology Questionnaire [19], which was modelled on the questionnaire developed and validated by the European Prospective Investigation into Cancer and Nutrition [20]. Anonymised UK-CCSG raw dataset is present in [S1 File](#). For the NIH-CCFR dataset, each study participant completed a standardised family history, personal exposure and baseline epidemiologic questionnaire either in person (University of Southern California site), by telephone (Fred Hutchinson cancer research Centre, University of Southern California and University of Queensland Melbourne sites) or by mail (University of Hawaii, Cancer Care Ontario and Mayo Clinic sites) [18]. Questionnaires were customised by the participating centres for local usage, in particular for different language conventions and brand names, and added some questions of local interests. Copy of the phase 1 baseline family history and baseline epidemiologic questionnaires from all 6 sites can be downloaded from: <http://coloncfr.org/questionnaires>.

All participants provided written informed consent at the time of the interview and the study design was approved by the Institutional Review Boards at each NIH-CCFR site. The UK-CCSG study as well as the joint analysis of the UK-CCSG and NIH-CCFR data were approved by the Leeds East Research Ethics Committee.

Because of sample numbers, only self-reported non-Hispanic white individuals were included in the analysis. A baseline epidemiologic questionnaire containing details about medical history and medication use (including use of aspirin, NSAIDs or both) was completed by participants in both studies; the measurement instrument differed between the studies overall but were equivalent for assessing NSAID usage ([S1 Table](#)).

### SNP selection and genotyping

Literature review was carried out using PubMed and Google Scholar to identify SNPs in putative genes. A combination of keywords such as- “aspirin”, “NSAID”, “pharmacogenetics”, “polymorphisms”, “SNPs”, “gene variant”, “colorectal adenoma” and “colorectal cancer”, was used to search for relevant literature published between 1990 and 2015 in the search engines. On PubMed, this resulted in 103 abstracts. All studies presenting original data on SNP and colorectal adenoma or carcinoma risk association, or interaction between SNP and aspirin (or NSAID) use in relation to colorectal adenoma or carcinoma were retrieved and reviewed. Types of articles reviewed included original article, editorial letter, conference abstract, observational study, meta-analysis, review, systemic review and randomized controlled trial. The UK-CCSG study collaborators crosschecked candidate SNP selection from the literature. From the published studies reviewed until May 2015, a total of 42 SNPs from 15 candidate genes were selected for analysis ([S2 Table](#)).

We selected genes and SNPs as follows: (i) from previous studies of colorectal adenoma or cancer where statistical evidence—after correction for multiple testing—of an interaction with NSAID use (including aspirin) had been observed (*ALOX15*, *IL16*, *MDR1*, *MGST1*, *NFkB*, *UGT1A6*, *PTGS1* and *PTGS2*) [[6](#), [9](#), [12](#), [14](#), [15](#), [21–23](#)]; (ii) SNPs in the genes *CES2* and *PAFAH1B2* were selected as these genes have been shown to metabolize aspirin in intestine and blood, respectively, but had not been tested for interaction with aspirin use in relation to CRC risk previously [[24](#), [25](#)]; (iii) SNPs in genes involved in the metabolism of aspirin that have been shown to be associated with colorectal cancer or adenoma risk (*CYP2C9*) [[26](#)] and; (iv) SNPs in genes that are direct or indirect targets of aspirin and have been shown to be associated with colorectal cancer or adenoma risk (*IkBkB*, *CCAT2*, 20p12 locus, *NCF4* and *ODC1*) [[6](#), [8](#), [13](#), [16](#), [27](#)].

No SNPs were genotyped for the NIH-CCFR dataset as these samples had been the subject of genome-wide genotyping [[28](#)] using Illumina Human 1M, IM Duo and Omni1 arrays ([S3 Table](#)). Taqman allelic discrimination assay (Applied Biosystems, Paisley, UK) was used for the UK-CCSG sample set to supplement genotyping with an Illumina HumanExome Bead-Chip array v1.1 (Illumina, San Diego, USA) ([S3 Table](#)). A detailed description of genotyping, quality assurance and control, and imputation is provided in [S2 File](#).

SNPs were excluded if they were tri-allelic; had a call rate of <98%; had a minor allele frequency (MAF) of <4%; or there was evidence of being out of Hardy Weinberg equilibrium (HWE) in controls ( $P < 0.001$  after multiple tests correction). Overall, 15 of the 42 SNPs were removed from analysis as the observed MAF was <4%. For the remaining SNPs, all were in HWE and the MAF between the two datasets was similar ([S4 Table](#)).

### Statistical analysis

Common data elements were defined for both datasets to produce common definitions and coding terms ([S1 Table](#)). Continuous variables such as BMI, alcohol and physical activity were converted to dichotomous variables by a median split. Comparison of SNP minor allele frequency between controls in two datasets was carried out using Fisher's exact test ([S4 Table](#)). SNPs within the same chromosome were tested for linkage disequilibrium ( $R^2$ ) in controls in



both datasets (S1 and S2 Figs). Each genotyped SNP was coded as 0, 1, or 2 for the number of copies of minor allele and imputed SNP, such as rs20417 in the NIH-CCFR dataset, was coded based on the “expected” number of copies of the minor allele.

The odds ratio (OR) and 95% confidence interval (CI) for associations between known epidemiological risk factors, “aspirin only” use, and SNP genotype with CRC risk were assessed using logistic regression models adjusted for age, sex and study site separately for each study. Each SNP was tested for association with colorectal cancer risk using logistic regression and assuming an additive model of inheritance. The interaction of SNP genotype with “aspirin only” use in relation to CRC risk was investigated. Participants who took aspirin only were included in the analysis, whereas, users of both aspirin and other NSAIDs (UK-CCSG  $n = 49$ , NIH-CCFR  $n = 160$ ) or other NSAIDs only (UK-CCSG  $n = 258$ , NIH-CCFR  $n = 261$ ) were excluded from the analysis. Regular aspirin use was defined as daily aspirin intake for 3 months or longer in the UK-CCSG dataset whereas it was defined as twice a week aspirin intake for more than a month in the NIH-CCFR dataset (S1 Table). GxE interaction was tested using logistic regression of the cross product of the presence of variant allele and dichotomous regular use of aspirin-only. The likelihood ratio test was used to assess the statistical significance of the interaction with adjustment for age, sex and study site.

Meta-analysis of the association and interaction tests for the SNPs and “aspirin only” use with CRC risk in both datasets was carried out. Estimates of log odds ratios and standard error from both datasets, which were adjusted for age, sex and study site, were used to calculate combined risk estimates using random-effects models where the log OR were weighted by the method of DerSimonian and Laird [29]. To test for heterogeneity between the estimates from the two datasets, Cochran’s Q-test and Higgin’s I-squared statistic [30] was calculated. All tests were carried out using an additive inheritance model. All  $P$ -values were two-sided and the significance threshold was set at  $\leq 0.001$  to allow for multiple testing (Bonferroni correction for 42 SNPs,  $0.05/42 = 0.001$ ). All analyses were conducted in Stata V12 (Stata Corp., College Station, USA). Checklist outlining information about the justification for the study and the methodology employed is provided in S3 File.

## Results

### Baseline epidemiological characteristics of cases and controls

Overall, the UK-CCSG dataset consisted of 1910 cases and 1275 controls and the NIH-CCFR dataset consisted of 1415 cases and 986 controls. Characteristics of the study population are presented in Table 1 (Further information in S5 Table). Compared to the UK-CCSG dataset, the NIH-CCFR dataset had higher proportion of cases under the age of 50 (Table 1), resulting from the differences in case ascertainment strategies. Association of known epidemiological risk factors, including aspirin use, with CRC risk in both studies was consistent with the existing literature (Table 1). Due to the availability of participant’s data on weight at the age 20 in both datasets, we tested for association between BMI at age 20 and CRC risk. We observed a positive association between BMI and CRC risk which is consistent with a prospective study, which had shown that weight gain during early adulthood increased risk of colon cancer [31]. Association between family history and CRC risk in the NIH-CCFR dataset was not tested since the study sites used different case recruitment strategies, some of which selected cases based on the family history and age at cancer diagnosis [18].

### SNP association with CRC risk

Each SNP was assessed for its association with CRC risk using logistic regression separately by dataset (S6 Table). Meta-analysis of the datasets showed a reduced risk of CRC associated with

**Table 1. Characteristics of population based UK-Colorectal Cancer Study Group (UK-CCSG) and NIH-Colon Cancer Family Registry (NIH-CCFR) datasets.** For odds ratio comparisons, the baseline level is indicated.

	UK-Colorectal Cancer Study Group (N = 3185)				NIH-Colon Cancer Family Registry (N = 2401)			
	Controls (n = 1275), n (%)	Cases (n = 1910), n (%)	Odds Ratio (95% CI)	P-value	Controls (n = 986), n (%)	Cases (n = 1415), n (%)	Odds Ratio (95% CI)	P-value
<b>Sex, n(%)</b>								
Male (baseline)	635 (49.8)	1124 (58.8)			473 (48.0)	731 (51.7)		
Female	639 (50.2)	786 (41.2)	0.69 (0.60–0.80)	<0.001	513 (52.0)	684 (48.3)	0.86 (0.73–1.02)	0.08
<b>Age (in years)<sup>a</sup>, n (%)</b>								
<50	42 (3.3)	106 (5.6)	-	-	154 (15.6)	637 (45.0)	-	-
50–59	167 (13.1)	309 (16.2)			299 (30.3)	334 (23.6)		
60–69	493 (38.6)	646 (33.8)			305 (30.9)	314 (22.2)		
70–79	505 (39.6)	685 (35.9)			228 (23.1)	130 (9.2)		
80–89	69 (5.4)	161 (8.4)			-	-		
≥90	-	3 (0.2)			-	-		
<b>Primary cancer site, n (%)</b>								
Colon	-	1222 (64.0)	-	-	-	804 (62.6)	-	-
Rectum	-	688 (36.0)			-	480 (37.4)		
<b>BMI at 20 years<sup>b</sup>, n(%)</b>								
Low (baseline)	628 (49.9)	821 (44.8)			481 (49.5)	575 (41.3)		
High	630 (50.1)	1013 (55.2)	1.23 (1.07–1.42)	0.005	490 (50.5)	816 (58.7)	1.39 (1.18–1.64)	<0.0001
<b>Family history of cancer<sup>c</sup>, n(%)</b>								
No (baseline)	209 (47.4)	195 (29.5)			-	-		
First or (and) second degree relative	232 (52.6)	466 (70.5)	2.15 (1.68–2.77)	1.98 x 10 <sup>-9</sup>	-	-	-	-
<b>Cigarette smoking<sup>d</sup>, n (%)</b>								
No (baseline)	555 (43.7)	710 (37.6)			408 (41.4)	557 (39.4)		
Yes	715 (56.3)	1179 (62.4)	1.29 (1.12–1.49)	0.001	578 (58.6)	856 (60.6)	1.08 (0.92–1.28)	0.34
<b>Alcohol intake<sup>e</sup>, n(%)</b>								
Low (baseline)	642 (50.6)	741 (39.6)			146 (48.2)	219 (42.3)		
High	626 (49.4)	1130 (60.4)	1.56 (1.34–1.81)	1.01 x 10 <sup>-9</sup>	157 (51.8)	299 (57.7)	1.27 (0.95–1.69)	0.10
<b>Physical activity<sup>f</sup>, n(%)</b>								
Low (baseline)	622 (49.1)	976 (52.3)			-	-		
High	646 (50.9)	888 (47.7)	0.88 (0.76–1.01)	0.07	-	-	-	-
<b>Regular aspirin only use<sup>g</sup>, n(%)</b>								
No (baseline)	848 (76.8)	1421 (81.4)			518 (64.7)	874 (75.2)		
Yes	256 (23.2)	324 (18.6)	0.76 (0.63–0.91)	0.003	283 (35.3)	531 (24.8)	0.60 (0.50–0.73)	4.80 x 10 <sup>-7</sup>
<b>Regular NSAID use<sup>g</sup>, n (%)</b>								
No (baseline)	848 (66.9)	1421 (75.3)			518 (52.9)	874 (62.2)		

(Continued)

Table 1. (Continued)

	UK-Colorectal Cancer Study Group (N = 3185)				NIH-Colon Cancer Family Registry (N = 2401)			
	Controls (n = 1275), n (%)	Cases (n = 1910), n (%)	Odds Ratio (95% CI)	P-value	Controls (n = 986), n (%)	Cases (n = 1415), n (%)	Odds Ratio (95% CI)	P-value
Yes	420 (33.1)	467 (24.7)	0.66 (0.57–0.78)	3.58 x 10 <sup>-7</sup>	461 (47.1)	531 (37.8)	0.68 (0.58–0.81)	6.04 x 10 <sup>-6</sup>

Continuous variables such as BMI, alcohol intake and physical activity were dichotomised by placing a cutoff point at the median split in controls. Odds ratio was calculated using logistic regression and depicts association with colorectal cancer risk.

<sup>a</sup> Age at the time of diagnosis for cases and interview for controls

<sup>b</sup> Body Mass Index (BMI) cut-off point in UK-CCSG and NIH-CCFR dataset is 21.8 kg/m<sup>2</sup> and 21.5 kg/m<sup>2</sup> respectively. Participants below the cut-off point are categorised as “Low” and above the cut-off point are categorised as “High” in the respective datasets.

<sup>c</sup> Association between family history of cancer and CRC risk not calculated for the NIH-CCFR dataset due to the different case recruitment strategies employed by the study sites

<sup>d</sup> “Yes” is defined as ever smoked 1 cigarette a day for 3 months or longer. “No” is defined as never smoked a cigarette.

<sup>e</sup> Alcohol intake cut off point in UK-CCSG and NIH-CCFR dataset is 5.6 units/day and 0.89 units/day respectively. Participants below the cut-off point are categorised as “Low” and above the cut-off point are categorised as “High” in the respective datasets.

<sup>f</sup> Physical activity cut off point in UK-CCSG dataset 3 hours/week. Participants below the cut-off point are categorised as “Low” and above the cut-off point are categorised as “High” in the respective datasets.

<sup>g</sup> Regular aspirin or NSAID use is defined as regular intake for a period of 3 months or longer in the UK-CCSG dataset whereas it is defined as regular use of at least two pills per week for at least one month in the NIH-CCFR dataset.

<https://doi.org/10.1371/journal.pone.0192223.t001>

the presence of variant allele of SNPs rs6983267 (OR = 0.86, 95% CI = 0.79–0.94,  $P = 0.001$ ,  $I^2 = 0$ ), rs2302615 (OR = 0.85, 95% CI = 0.74–0.98,  $P = 0.02$ ,  $I^2 = 0$ ) and rs11694911 (OR = 0.85, 95% CI = 0.74–0.96,  $P = 0.01$ ,  $I^2 = 0$ ) at *CCAT2* and the *ODC1* gene locus, respectively (S7 Table).

Site-specific meta-analysis of colon and rectum showed approximately 20% decrease in colon cancer risk only in the presence of *CYP2C9* rs1799853 variant allele (OR = 0.79, 95% CI = 0.65–0.95,  $P = 0.01$ ,  $I^2 = 0$ ) and *ODC1* rs2302615 variant allele (OR = 0.80, 95% CI = 0.69–0.93,  $P = 0.004$ ,  $I^2 = 0$ ) (S8 and S9 Tables). No site-specific association was observed for the *CCAT2* rs6983267 variant allele, as it was associated with reduced risk of both colon cancer (OR = 0.86, 95% CI = 0.78–0.95,  $P = 0.002$ ,  $I^2 = 0$ ; S9 Table) and rectal cancer (OR = 0.85, 95% CI = 0.75–0.95,  $P = 0.005$ ,  $I^2 = 0$ ; S10 Table).


## Gene x aspirin-only use interactions

Each SNP was assessed for an interaction with aspirin-only use in relation to CRC risk, separately by dataset and combined in a meta-analysis. In the meta-analysis, SNP rs2070959 in the *UGT1A6* gene showed evidence of an interaction between aspirin-only use and CRC risk ( $P_{\text{interaction}} = 0.01$ ,  $I^2 = 0$ ), whereby aspirin users with wild-type genotype were associated with 23% lower CRC risk (OR = 0.77, 95% CI = 0.69–0.86) compared to negligible risk reduction in variant allele carriers (OR = 0.92, 95% CI = 0.86–0.99) (Fig 1; S11 and S12 Tables). A second SNP in *UGT1A6* gene: rs1105879, which is in high linkage disequilibrium (LD) with rs2070959 ( $R^2 = 0.90$ ), showed similar evidence (Fig 1; S11 and S12 Tables; S1 and S2 Figs). No significant difference in risk reduction was observed between wild-type genotype and variant allele carriers for both SNPs in non-users of aspirin.


Meta-analysis of the GxE interaction stratified by tumour site showed an interaction between SNP rs2070959 and aspirin-only use in relation to colon cancer risk ( $P_{\text{interaction}} = 0.006$ ): aspirin users with the wild-type genotype showed a 26% lower risk of colon cancer than non-users with wild-type genotype (OR = 0.74, 95% CI = 0.65–0.84), whereas, no




A



B



C



**Fig 1. Meta-analysis of interaction between SNP variant allele, aspirin-only use and colorectal cancer risk.** (A) Forest plot depicting meta-analysis odds ratio of GxE interaction term. I-squared is the measure of the variation in odds ratio attributable to heterogeneity [30] and *P*-value tests for heterogeneity between the UK-CCSG and


NIH-CCFR datasets. (B) Association between *UGT1A6* SNP rs2070959 (T181A) variant allele and CRC risk stratified by aspirin use.  $P_{\text{interaction}} = 0.01$ . (C) Association between *UGT1A6* SNP rs1105879 (R184S) variant allele and CRC risk stratified by aspirin use.  $P_{\text{interaction}} = 0.02$ . \* $P$ -value for association  $< 0.001$ ; UK-CCSG: UK-Colorectal Cancer Study Group; NIH-CCFR: NIH-Colon Cancer Family Registry.

<https://doi.org/10.1371/journal.pone.0192223.g001>

difference in risk reduction was observed in variant allele carriers regardless of the aspirin use status (Fig 2A). We observed a similar direction and magnitude of interaction between SNP rs1105879 and aspirin-only use in relation to colon cancer risk ( $P_{\text{interaction}} = 0.008$ ). No evidence of interaction was observed between either SNP, aspirin use and rectal cancer risk (Fig 2B). Haplotype analysis of SNPs was not conducted as the SNPs were in high LD and would not have provided additional statistical power to observe any potential interaction (S1 and S2 Figs).

## Sensitivity analysis

The predefined analysis plan included participants of all ages. However, the UK-CCSG cohort represents population-based cases (6.9% of cases below the age of 50 years) whereas the NIH-CCFR cohort is enhanced for early onset (47.7% of cases below the age of 50 years). Since aspirin is prescribed prophylactically for cardiovascular diseases after the age of 50, it is likely that the participants under the age of 50 may not be exposed to aspirin. Hence, we



**Fig 2. Meta-analysis of site-specific interaction between SNP variant allele, aspirin-only use and (A) colon cancer risk and (B) rectal cancer risk.** (A) Association between *UGT1A6* rs2070959 (T181A) variant allele and colon cancer risk stratified by aspirin use ( $P_{\text{interaction}} = 0.006$ ); association between *UGT1A6* rs1105879 (R184S) variant allele and colon cancer risk stratified by aspirin use ( $P_{\text{interaction}} = 0.008$ ). (B) Association between *UGT1A6* rs2070959 (T181A) variant allele and rectal cancer risk stratified by aspirin use ( $P_{\text{interaction}} = 0.22$ ); association between *UGT1A6* rs1105879 (R184S) variant allele and rectal cancer risk stratified by aspirin use ( $P_{\text{interaction}} = 0.26$ ). Forest plot depicting meta-analysis odds ratio of gene x environment interaction term. I-squared is the measure of the variation in odds ratio attributable to heterogeneity [30] and  $P$ -value tests for heterogeneity between the UK-CCSG and NIH-CCFR datasets. \* $P$ -value for association  $< 0.05$ ; CC: Colon Cancer; RC: Rectal Cancer; UK-CCSG: UK-Colorectal Cancer Study Group; NIH-CCFR: NIH-Colon Cancer Family Registry.

<https://doi.org/10.1371/journal.pone.0192223.g002>

performed sensitivity analysis by excluding all participants under the age of 50 and carried out GxE interaction test between only aspirin use, SNP variant allele and CRC risk. Compared to the analysis carried out in all participants, we observed similar direction and magnitude of interaction between SNPs in the *UGT1A6* genes, only aspirin use and CRC risk age restricted analysis ( $P_{\text{interaction}} = 0.009$ ,  $I^2 = 0$  for rs2070959;  $P_{\text{interaction}} = 0.01$ ,  $I^2 = 0$  for rs1105879; [S13 Table](#)).

## Discussion

In the current meta-analysis, we observed association between the SNP at *CCAT2* gene locus with reduced CRC risk, which was noteworthy after multiple test correction and congruent with the literature [26, 32]. Potential site-specific association between rs1799853 in *CYP2C9* and colon cancer risk was complemented by the assessment of the difference in *CYP2C9* protein expression between colon and rectum in the Human Protein Atlas. Medium protein expression is observed in the colon but not rectal tissue [33], suggesting that there may be relevant differences in site-specific metabolism. SNP rs1799853 is a nonsynonymous coding variant (p.R144C) which codes for a *CYP2C9* enzyme with reduced activity and metabolic capacity [34]. As *CYP2C9* enzyme metabolises pro-carcinogenic xenobiotic compounds such as- polycyclic aromatic hydrocarbons and heterocyclic aromatic amines- in the intestinal epithelium, it leads to an increased risk of cancer [35]. Hence, the carriers of the SNP rs1799853 variant allele may observe reduced risk of developing colon cancer compared to rectal cancer.

Interestingly, we observed a potential site-specific association for decrease in colon cancer risk in the presence of *ODC1*'s rs2302615 A allele. Whilst the association was not significant after multiple test correction, it was complemented by the study carried out by Zell *et al.* which observed decreased probability of survival in patients diagnosed with rectal cancer and carrying rs2302615 A allele (*ODC1* GA/ AA genotype HR = 2.92, 95% CI = 1.22–7.03) but not in colon cancer patients (*ODC1* GA/ AA genotype HR = 1.76, 95% CI = 0.85–3.63) [36]. Ornithine decarboxylase (*ODC*) regulates polyamine synthesis. Upregulated polyamine metabolism is associated with increased risk of colorectal cancer. Regulation of *ODC1* is carried out by E-box transcription factors, chiefly- transcriptional activator c-MYC and transcriptional repression MAD1. Tissue specific RNA-seq data in the Human Protein Atlas show 7.5 and 5.8 transcripts per million of *MAD1* in colon and rectum tissues, suggesting slightly higher expression of *MAD1* in the colon compared to rectum [33]. Coupled this with the observation suggesting preferential binding of *MAD1* to *ODC1* promoter containing A allele in two colon cancer cell lines- HT29 and HCT116 [36], it is likely that the carriers of rs2302615's variant allele may observe reduced risk of developing colon cancer.

Upon assessing GxE interaction, aspirin-only users with wild-type genotype of the SNPs in *UGT1A6* gene gave suggestive evidence of decreased risk of CRC or colon cancer but not in variant allele carriers. The UDP glucuronosyltransferase 1A6 (*UGT1A6*) protein is involved in metabolism of salicylic acid through glucuronidation [37]. A study in liver microsomes and urine analysis in young volunteers following aspirin intervention has shown that homozygous mutant carriers of the SNPs rs2070959 and rs1105879 have a higher metabolic activity than wild-type carriers [37, 38], hence wild-type carriers are likely to benefit from aspirin intervention, consistent with our interaction data. In previous studies, a significant interaction between *UGT1A6* SNPs, aspirin use and colorectal adenoma risk has been observed whereby, carriers of variant allele were associated with lower risk of colorectal adenoma in aspirin users compared to non-users [17, 39]. This is in contrast to our findings where CRC risk was decreased in aspirin users with wild-type genotype compared to non-users. Analysis for the interaction between the *UGT1A6* SNP variant allele, any NSAID (including aspirin) use and CRC risk in the current study revealed no difference in the direction of association compared to the

interaction involving aspirin only use (data not presented). Whilst testing for the source of the contradiction between these observations was beyond the remit of the current study, it is plausible to attribute the differences to the distinction between the key genetic and epigenetic molecular factors between adenoma and carcinoma that may make carcinoma cells more sensitive to aspirin intervention [40]. One of the key changes observed during adenoma to carcinoma progression is change in gene expression [41, 42]. One of the genes downregulated during the adenoma-carcinoma progression is *UGT1A6*. As the wild-type allele has lower metabolic activity compared to the variant allele, participants with wild-type genotype are likely to retain active metabolites of aspirin longer than the mutant allele carriers; hence, deriving greater chemopreventive benefit. Moreover, this is in keeping with observations in chemoprevention trials CAPP1 and CAPP2 where the chemopreventive effect of aspirin was restricted to colorectal cancer incidence with apparently limited impact on colorectal adenoma development [43, 44]. Additionally, the site-specific interaction of *UGT1A6* SNPs with colon cancer has been observed previously, albeit without statistical significance due to small study size consisting of only 422 cases and 481 population controls [45].

Interestingly, SNP rs11694911, which is located downstream to the *ODC1* gene has previously been shown to be associated with increased risk of colorectal adenoma [16]. In contrast, we observed an association between the SNP variant allele and 16% reduction in colorectal cancer risk. Sample sizes in both studies were reasonable and to date, no functional evidence about the SNP is available. Among individuals with the wild type rs2965667 SNP at *MGST1* locus, we found decreased CRC risk among aspirin users; this finding is consistent in direction but not as strong as the findings from the GWAS study of Nan *et al.* 2015 where the study involved over 8000 cases and controls. However, for individuals carrying the variant allele, that study showed significantly increased risk of CRC among NSAID users, a result inconsistent with our observations. The current study didn't observe evidence of interaction between variant alleles of SNPs in previously reported genes- *ALOX15*, *IL16*, *MDR1*, *NFkB*, *PTGS1* and *PTGS2*- with aspirin only use and CRC or colon cancer risk. This could in part be attributed to the differences in the choice of drug definition for carrying out the interaction test. Previous studies carried out GxE interaction test with any NSAID use (including aspirin) and CRC risk. The broad range of NSAIDs used to carry out the test includes drugs with different pharmacokinetic and pharmacodynamics mechanisms thus precluding the assessment of the true source of interaction.

An *ad hoc* power calculation was performed in Quanto V1.2.4 (<http://biostats.usc.edu/Quanto.html>) using the outcomes observed in the current study to assess the number of cases and controls needed to carry out an interaction test between *UGT1A6* SNP, aspirin only use and colorectal cancer risk with two-sided *P* value of 0.002 (corrected for multiple tests) and 80% power. Assuming an unmatched case-control (1:1 ratio) study design, population CRC risk ( $P_o$ ) of 6%, SNP minor allele frequency of 31% with additive mode of inheritance, genetic effect ( $R_G$ ) of 5%, environmental effect (aspirin only users;  $R_E$ ) of 26% and population prevalence of aspirin users ( $P_E$ ) of 20%: we would require 7057 cases and controls to observe an GxE interaction effect ( $R_{GE}$ ) of 20%. This highlights that the current study with a combined total of 3325 cases and 2262 controls had limited statistical power for GxE interaction. Whilst we did not adjust analysis for multiple test correction, hence increasing the probability of false positive results, we did observe results for some of the SNPs that are congruent with previously published studies where correction for multiple testing was applied. Even though these results are consistent with ours, all positive results should be regarded as hypothesis-generating and should be investigated in other independent datasets.

Additionally, we could not investigate whether there was a dose-response relationship among aspirin users because dose information was not recorded in the NIH-CCFR dataset.

Other NSAIDs were also used by participants in both studies but numbers precluded detailed examination of each. Compared with previous studies where analysis for interaction was carried out in all users of NSAIDs—and thus limiting identification of the true source of interaction as each NSAID affect different biological pathways—our study was restricted to interaction in aspirin-only users.

In summary, our results suggest variant alleles of the genes involved in aspirin pathways, *CYP2C9*, *ODCI* and *UGT1A6*, may be involved in the modification of CRC or colon cancer risk independently or in conjunction with aspirin use.

## Supporting information

### **S1 File. Anonymised UK-CCSG raw dataset.**

(XLSX)

### **S2 File. A detailed description of genotyping, quality assurance and control, and imputation.**

(DOCX)

### **S3 File. Meta-analysis of genetic association studies checklist.**

(DOCX)

**S1 Table. Standardized definitions of common data elements between the UK-CCSG and NIH-CCFR datasets.** + Smoking includes cigarettes, cigar and pipes. ^Alcohol includes beer, cider, wine, sherry, other fortified wine, sake, champagne and spirits.

(DOCX)

### **S2 Table. List of SNPs from genes included in the study.**

(DOCX)

### **S3 Table. List of SNPs genotyped across different platforms in UK-CCSG and NIH-CCFR datasets.**

(DOCX)

**S4 Table. Comparison of observed minor allele frequency of SNPs between UK-Colorectal Cancer Stud Group and NIH-Colon Cancer Study Registry.** \* Observed minor allele frequency (MAF) in controls was compared to the MAF reported for Phase I GBR and Phase I CEU population from 1000 Genomes database in UK-CCSG and NIH-CCFR datasets respectively using Fisher's exact test. + Observed MAF in controls of the two datasets were compared using Fisher's exact test. ^ rs16973225 and rs5277 were only genotyped in cases in the NIH-CCFR dataset.

(DOCX)

**S5 Table. Baseline epidemiological characteristics data distribution within the UK-CCSG and NIH-CCFR datasets.** a, Total number of subjects calculated from only CCO, UQM and FHCRC study sites.

b, *P*-value calculated using Fisher's exact test for categorical variables and Mann-Whitney U test for continuous variables.

LTRI = Lunenfeld-Tanenbaum Research Institute, Ontario; USC = University of Southern California; UoM = University of Melbourne; MC = Mayo Clinic; FHCRC = Fred Hutchinson Cancer Research Centre; UHI = University of Hawaii Cancer Center.

(DOCX)

**S6 Table. Association between SNP variant allele and colorectal cancer risk.** \* *P*-value for association adjusted for age, sex and study site.

CI, Confidence Interval

n, Number of subjects.  
(DOCX)

**S7 Table. Meta-analysis of association between SNP variant allele and colorectal cancer risk.** \**P*-value for association adjusted for age, sex and study site.

+*P*-value for Cochran's Q-test for heterogeneity.

CI, Confidence Interval.

(DOCX)

**S8 Table. Association between SNP variant allele and site-specific colorectal cancer risk.**

+*P*-value for association adjusted for age, sex and study site.

CI, Confidence Interval

n, Number of subjects.

(DOCX)

**S9 Table. Meta-analysis of association between SNP variant allele and colon cancer risk.**

\**P*-value for association adjusted for age, sex and study site.

+*P*-value for Cochran's Q-test for heterogeneity.

CI, Confidence Interval.

(DOCX)

**S10 Table. Meta-analysis of association between SNP variant allele and rectal cancer risk.**

\**P*-value for association adjusted for age, sex and study site.

+*P*-value for Cochran's Q-test for heterogeneity.

CI, Confidence Interval.

(DOCX)

**S11 Table. Interaction between SNP variant allele, aspirin only use and colorectal cancer.**

+*P*-value for association adjusted for age, sex and study site.

\**P*-value for interaction between SNP variant allele, aspirin use and colorectal cancer risk calculated using Likelihood ratio test. *P*-value is adjusted for age, sex and study site.

OR, Odds Ratio

CI, Confidence Interval

n, Number of subjects.

(DOCX)

**S12 Table. Meta-analysis of interaction between SNP variant allele, aspirin only use and colorectal cancer.** +*P*-value for association adjusted for age, sex and study site.

\**P*-value for interaction between SNP variant allele, aspirin use and colorectal cancer risk calculated using Likelihood ratio test. *P*-value is adjusted for age, sex and study site.

~*P*-value for Cochran's Q-test for heterogeneity

OR, Odds Ratio

CI, Confidence Interval.

(DOCX)

**S13 Table. Sensitivity analysis- meta-analysis of interaction between SNP variant allele, aspirin only use and colorectal cancer, in cases and controls with age more than 50 years.**

+*P*-value for association adjusted for age, sex and study site.

\**P*-value for interaction between SNP variant allele, aspirin use and colorectal cancer risk calculated using Likelihood ratio test. *P*-value is adjusted for age, sex and study site.

~*P*-value for Cochran's Q-test for heterogeneity

OR, Odds Ratio



CI, Confidence Interval.  
(DOCX)

**S1 Fig. Linkage disequilibrium ( $R^2$ ) heat maps for SNPs in the UK-Colorectal Cancer Study Group dataset.**  
(DOCX)

**S2 Fig. Linkage disequilibrium ( $R^2$ ) heat maps for SNPs in the NIH-Colon Cancer Family Registry dataset.**  
(DOCX)

## Acknowledgments

The authors thank Polly A. Newcomb, Steve Gallinger and John Baron for helpful discussions and support.

*Conflict of interest statement:* John Burn and Cornelia M. Ulrich are consultant/ advisory board member of Bayer Pharma who manufacture aspirin. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Other authors have declared that no competing interest exist.

## Author Contributions

**Conceptualization:** Harsh Sheth, Emma Northwood, Jennifer H. Barrett, Robert Haile, Graham Casey, Mark Jenkins, Aung Ko Win, John L. Hopper, Loic Le Marchand, Noralane M. Lindor, Stephen N. Thibodeau, John D. Potter, John Burn, D. Timothy Bishop.

**Data curation:** Faye Elliott, Jennifer H. Barrett, David Forman, C. Roland Wolf, Gillian Smith, Robert Haile, Graham Casey, Mark Jenkins, Aung Ko Win, John L. Hopper, Loic Le Marchand, Noralane M. Lindor, Stephen N. Thibodeau, John D. Potter, D. Timothy Bishop.

**Formal analysis:** Harsh Sheth, Emma Northwood, Cornelia M. Ulrich, Faye Elliott.

**Funding acquisition:** Jennifer H. Barrett, David Forman, C. Roland Wolf, Gillian Smith, Robert Haile, Graham Casey, Mark Jenkins, Aung Ko Win, John L. Hopper, Loic Le Marchand, Noralane M. Lindor, Stephen N. Thibodeau, John D. Potter, John Burn, D. Timothy Bishop.

**Methodology:** Harsh Sheth, Dominique Scherer, Michael S. Jackson, D. Timothy Bishop.

**Project administration:** Harsh Sheth, Emma Northwood, Jennifer H. Barrett, D. Timothy Bishop.

**Resources:** Dominique Scherer, Graham Casey.

**Supervision:** Emma Northwood, Cornelia M. Ulrich, Faye Elliott, Michael S. Jackson, Mauro Santibanez-Koref, John Burn, D. Timothy Bishop.

**Writing – original draft:** Harsh Sheth.

**Writing – review & editing:** Harsh Sheth, Cornelia M. Ulrich, Dominique Scherer, Jennifer H. Barrett, Michael S. Jackson, Mauro Santibanez-Koref, Aung Ko Win, John D. Potter, John Burn, D. Timothy Bishop.

## References

1. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. *The Lancet*

- Oncology. 2012; 13(5):518–27. Epub 2012/03/24. [https://doi.org/10.1016/S1470-2045\(12\)70112-2](https://doi.org/10.1016/S1470-2045(12)70112-2) PMID: 22440112.
2. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. *Annals of internal medicine*. 2013; 159(2):77–85. Epub 2013/07/17. <https://doi.org/10.7326/0003-4819-159-2-201307160-00002> PMID: 23856681; PubMed Central PMCID: PMC3713531.
3. Rothwell PM, Price JF, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. *The Lancet*. 2012; 379(9826):1602–12. [https://doi.org/10.1016/S0140-6736\(11\)61720-0](https://doi.org/10.1016/S0140-6736(11)61720-0)
4. Burn J, Gerdes A-M, Macrae F, Mecklin J-P, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *The Lancet*. 2011; 378(9809):2081–7. [https://doi.org/10.1016/S0140-6736\(11\)61049-0](https://doi.org/10.1016/S0140-6736(11)61049-0) PMID: 22036019
5. Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. *Nat Rev Cancer*. 2016; 16(3):173–86. <https://doi.org/10.1038/nrc.2016.4> PMID: 26868177
6. Seufert BL, Poole EM, Whitton J, Xiao L, Makar KW, Campbell PT, et al. IkappaBkbeta and NFkappaB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry. *Carcinogenesis*. 2013; 34(1):79–85. Epub 2012/09/25. <https://doi.org/10.1093/carcin/bgs296> PMID: 23002237; PubMed Central PMCID: PMC3534188.
7. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. *Nat Rev Clin Oncol*. 2012; 9(5):259–67. <https://doi.org/10.1038/nrclinonc.2011.199> PMID: 22473097
8. Hubner RA, Muir KR, Liu JF, Logan RF, Grainge MJ, Houlston RS. Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2008; 14(8):2303–9. Epub 2008/04/17. <https://doi.org/10.1158/1078-0432.ccr-07-4599> PMID: 18413818.
9. Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, et al. PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. *Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2005; 14(3):616–9. Epub 2005/03/16. <https://doi.org/10.1158/1055-9965.epi-04-0510> PMID: 15767339.
10. Liesenfeld DB, Botma A, Habermann N, Toth R, Weigel C, Popanda O, et al. Aspirin Reduces Plasma Concentrations of the Oncometabolite 2-Hydroxyglutarate: Results of a Randomized, Double-Blind, Crossover Trial. *Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2016; 25(1):180–7. Epub 2015/11/21. <https://doi.org/10.1158/1055-9965.epi-15-0697> PMID: 26585118.
11. Nan H, Hutter CM, Lin Y, et al. Association of aspirin and non-steroidal anti-inflammatory drug use with risk of colorectal cancer according to genetic variants. *Jama*. 2015; 313(11):1133–42. <https://doi.org/10.1001/jama.2015.1815> PMID: 25781442
12. Scherer D, Koepl LM, Poole EM, Balavarca Y, Xiao L, Baron JA, et al. Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: colon cancer family registry. *Genes Chromosomes Cancer*. 2014; 53(7):568–78. Epub 2014/03/29. <https://doi.org/10.1002/gcc.22167> PMID: 24677636.
13. Nan H, Morikawa T, Suuriniemi M, Imamura Y, Werner L, Kuchiba A, et al. Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. *J Natl Cancer Inst*. 2013; 105(24):1852–61. Epub 2013/12/10. <https://doi.org/10.1093/jnci/djt331> PMID: 24317174; PubMed Central PMCID: PMC3866156.
14. Makar KW, Poole EM, Resler AJ, Seufert B, Curtin K, Kleinstein SE, et al. COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations. *Cancer Causes Control*. 2013; 24(12):2059–75. Epub 2013/09/12. <https://doi.org/10.1007/s10552-013-0282-1> PMID: 24022467; PubMed Central PMCID: PMC3913564.
15. Kleinstein SE, Heath L, Makar KW, Poole EM, Seufert BL, Slattey ML, et al. Genetic variation in the lipoygenase pathway and risk of colorectal neoplasia. *Genes Chromosomes Cancer*. 2013; 52(5):437–49. Epub 2013/02/14. <https://doi.org/10.1002/gcc.22042> PMID: 23404351; PubMed Central PMCID: PMC3698944.
16. Barry EL, Mott LA, Sandler RS, Ahnen DJ, Baron JA. Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and aspirin chemoprevention. *Cancer prevention research (Philadelphia, Pa)*. 2011; 4(12):2072–82. Epub 2011/09/21. <https://doi.org/10.1158/1940-6207.capr-11-0300> PMID: 21930798; PubMed Central PMCID: PMC3232321.

17. Bigler J, Whitton J, Lampe JW, Fosdick L, Bostick RM, Potter JD. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. *Cancer research*. 2001; 61(9):3566–9. Epub 2001/04/28. PMID: [11325819](#).
18. Newcomb PA, Baron J, Cotterchio M, Gallinger S, Grove J, Haile R, et al. Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. *Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2007; 16(11):2331–43. Epub 2007/11/06. <https://doi.org/10.1158/1055-9965.epi-07-0648> PMID: [17982118](#).
19. Barrett JH, Smith G, Waxman R, Gooderham N, Lightfoot T, Garner RC, et al. Investigation of interaction between N-acetyltransferase 2 and heterocyclic amines as potential risk factors for colorectal cancer. *Carcinogenesis*. 2003; 24(2):275–82. Epub 2003/02/14. PMID: [12584178](#).
20. Kaaks R, Slimani N, Riboli E. Pilot phase studies on the accuracy of dietary intake measurements in the EPIC project: overall evaluation of results. *European Prospective Investigation into Cancer and Nutrition. International journal of epidemiology*. 1997; 26 Suppl 1:S26–36. Epub 1997/01/01. PMID: [9126531](#).
21. Angstadt AY, Hartman TJ, Lesko SM, Muscat JE, Zhu J, Gallagher CJ, et al. The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: Haplotype associations and gene–environment interactions. *Genes, Chromosomes and Cancer*. 2014; 53(6):454–66. <https://doi.org/10.1002/gcc.22157> PMID: [24822274](#)
22. Kraus S, Hummler S, Toriola AT, Poole EM, Scherer D, Kotzmann J, et al. Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. *Pharmacogenetics and genomics*. 2013; 23(8):428–37. Epub 2013/06/20. <https://doi.org/10.1097/FPC.0b013e3283631784> PMID: [23778325](#).
23. Barry EL, Sansbury LB, Grau MV, Ali IU, Tsang S, Munroe DJ, et al. Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence—data from a randomized clinical trial. *Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2009; 18(10):2726–33. Epub 2009/09/17. <https://doi.org/10.1158/1055-9965.epi-09-0363> PMID: [19755647](#); PubMed Central PMCID: PMC2769932.
24. Zhou G, Marathe GK, Willard B, McIntyre TM. Intracellular erythrocyte platelet-activating factor acetylhydrolase I inactivates aspirin in blood. *The Journal of biological chemistry*. 2011; 286(40):34820–9. Epub 2011/08/17. <https://doi.org/10.1074/jbc.M111.267161> PMID: [21844189](#); PubMed Central PMCID: PMC3186390.
25. Kubo T, Kim SR, Sai K, Saito Y, Nakajima T, Matsumoto K, et al. Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2). *Drug metabolism and disposition: the biological fate of chemicals*. 2005; 33(10):1482–7. Epub 2005/07/22. <https://doi.org/10.1124/dmd.105.005587> PMID: [16033949](#).
26. Wang H, Ren L, He Y, Wei Y, Chen Z, Yang W, et al. Association between cytochrome P450 2C9 gene polymorphisms and colorectal cancer susceptibility: evidence from 16 case-control studies. *Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2014; 35(5):4317–22. Epub 2014/01/15. <https://doi.org/10.1007/s13277-013-1566-5> PMID: [24414392](#).
27. Ryan BM, Zanetti KA, Robles AI, Schetter AJ, Goodman J, Hayes RB, et al. Germline variation in NCF4, an innate immunity gene, is associated with an increased risk of colorectal cancer. *International journal of cancer Journal international du cancer*. 2014; 134(6):1399–407. Epub 2013/08/29. <https://doi.org/10.1002/ijc.28457> PMID: [23982929](#); PubMed Central PMCID: PMC3947351.
28. Figueiredo JC, Lewinger JP, Song C, Campbell PT, Conti DV, Edlund CK, et al. Genotype-Environment Interactions in Microsatellite Stable/Microsatellite Instability-Low Colorectal Cancer: Results from a Genome-Wide Association Study. *Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2011; 20(5):758–66. <https://doi.org/10.1158/1055-9965.EPI-10-0675> PubMed PMID: PMC3089660. PMID: [21357381](#)
29. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled clinical trials*. 1986; 7(3):177–88. Epub 1986/09/01. PMID: [3802833](#).
30. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003; 327(7414):557–60. Epub 2003/09/06. <https://doi.org/10.1136/bmj.327.7414.557> PMID: [12958120](#); PubMed Central PMCID: PMC192859.
31. Renehan AG, Flood A, Adams KF, Olden M, Hollenbeck AR, Cross AJ, et al. Body mass index at different adult ages, weight change, and colorectal cancer risk in the National Institutes of Health-AARP Cohort. *American journal of epidemiology*. 2012; 176(12):1130–40. Epub 2012/11/29. <https://doi.org/10.1093/aje/kws192> PMID: [23186750](#).

32. Tenesa A, Farrington SM, Prendergast JG, Porteous ME, Walker M, Haq N, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. *Nature genetics*. 2008; 40(5):631–7. Epub 2008/04/01. <https://doi.org/10.1038/ng.133> PMID: 18372901; PubMed Central PMCID: PMC2778004.
33. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. *Science*. 2015; 347(6220):1260419. Epub 2015/01/24. <https://doi.org/10.1126/science.1260419> PMID: 25613900.
34. Crespi CL, Miller VP. The R144C change in the CYP2C9\*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. *Pharmacogenetics*. 1997; 7(3):203–10. Epub 1997/06/01. PMID: 9241660.
35. Ilett KF, Ingram DM, Carpenter DS, Teitel CH, Lang NP, Kadlubar FF, et al. Expression of monomorphic and polymorphic N-acetyltransferases in human colon. *Biochemical pharmacology*. 1994; 47(5):914–7. Epub 1994/03/02. PMID: 8135868.
36. Zell JA, Ziogas A, Ignatenko N, Honda J, Qu N, Bobbs AS, et al. Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2009; 15(19):6208–16. Epub 2009/10/01. <https://doi.org/10.1158/1078-0432.ccr-09-0592> PMID: 19789310; PubMed Central PMCID: PMC2769500.
37. Chen Y, Kuehl GE, Bigler J, Rimorin CF, Schwarz Y, Shen DD, et al. UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin. *Pharmacogenetics and genomics*. 2007; 17(8):571–9. Epub 2007/07/12. <https://doi.org/10.1097/01.fpc.0000236339.79916.07> PMID: 17622933.
38. Nagar S, Zalatoris JJ, Blanchard RL. Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. *Pharmacogenetics*. 2004; 14(8):487–99. Epub 2004/07/31. PMID: 15284531.
39. Chan AT, Tranah GJ, Giovannucci EL, Hunter DJ, Fuchs CS. Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma. *Journal of the National Cancer Institute*. 2005; 97(6):457–60. Epub 2005/03/17. <https://doi.org/10.1093/jnci/dji066> PMID: 15770010.
40. Bardhan K, Liu K. Epigenetics and Colorectal Cancer Pathogenesis. *Cancers*. 2013; 5(2):676–713. <https://doi.org/10.3390/cancers5020676> PubMed PMID: PMC3730326. PMID: 24216997
41. Pesson M, Volant A, Uguen A, Trillet K, De La Grange P, Aubry M, et al. A Gene Expression and Pre-mRNA Splicing Signature That Marks the Adenoma-Adenocarcinoma Progression in Colorectal Cancer. *PloS one*. 2014; 9(2):e87761. <https://doi.org/10.1371/journal.pone.0087761> PMID: 24516561
42. Carvalho B, Sillars-Hardebol AH, Postma C, Mongera S, Droste JTS, Obulkasim A, et al. Colorectal adenoma to carcinoma progression is accompanied by changes in gene expression associated with ageing, chromosomal instability, and fatty acid metabolism. *Cellular Oncology (Dordrecht)*. 2012; 35(1):53–63. <https://doi.org/10.1007/s13402-011-0065-1> PubMed PMID: PMC3308003. PMID: 22278361
43. Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. *Cancer prevention research (Philadelphia, Pa)*. 2011; 4(5):655–65. Epub 2011/05/06. <https://doi.org/10.1158/1940-6207.capr-11-0106> PMID: 21543343; PubMed Central PMCID: PMC3092423.
44. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet*. 2011; 378(9809):2081–7. Epub 2011/11/01. [https://doi.org/10.1016/S0140-6736\(11\)61049-0](https://doi.org/10.1016/S0140-6736(11)61049-0) PMID: 22036019; PubMed Central PMCID: PMC3243929.
45. Thompson CL, Plummer SJ, Merkulova A, Cheng I, Tucker TC, Casey G, et al. No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. *World journal of gastroenterology: WJG*. 2009; 15(18):2240–4. Epub 2009/05/14. <https://doi.org/10.3748/wjg.15.2240> PMID: 19437564; PubMed Central PMCID: PMC2682239.